Peptides / Weight and metabolic

Synthetic fragment · 16 amino acids · 1,815.1 Da

AOD-9604

Not approvedBanned in sport

AOD-9604 is a modified fragment of human growth hormone, made from its end piece with one added amino acid. It is not approved and is banned in sport, and its study results so far come from animal and lab studies, on pain and fat metabolism. PepBank shows 44 results on AOD-9604 from animal and lab studies. No study in people has reported results yet. Data as of 2026-10-30.

Also known as AOD9604, LAT-8881, LAT8881, Tyr-hGH(177-191), Tyr-somatostatin (177-191), hGH fragment 176-191

16 amino acids, from first to lastYLRIVQCRSVEGSCGF

Evidence level: Animal and lab studies onlyNo study in people has results. ClinicalTrials.gov lists 3 trials.

Results in people

0% of 44 results

Results in animals

82% of 44 results

Results in lab cells

18% of 44 results

From computer models

0% of 44 results

Overview

AOD-9604 at a glance

What it is	Synthetic fragment, 16 amino acids
Approval	Not approved for any use
In sport	Banned in sport (WADA S2)
Studies	10 studies with results. 7 of them gave AOD-9604, with 44 results. 36 in animals8 in lab cells
Clinical trials	3 registered: 0 active or planned, 3 with posted results
Community use	Fat loss; Joint use: injected into a joint, sometimes with hyaluronic acid (S2 says this is not a standard self-administration route)

The science

What is AOD-9604?

Synthetic 16-residue peptide: human growth hormone residues 177-191 with an added N-terminal tyrosine. Not an approved medicine in the US or EU.

Amino acids in one chain

The history of AOD-9604

2000
The oldest paper on AOD-9604 in PepBank is from 2000.
2019April
A registered trial of AOD-9604 started (NCT03865953).

AOD-9604 structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 16 amino acidsFrom the first amino acid to the last

Y1L+RIV5QC+RSV10−EGSCG15F

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

AOD-9604 is a synthetic fragment of 16 amino acids, with a ring, 1 disulfide bond, 1 changed amino acid.

Formula

C₇₈H₁₂₃N₂₃O₂₃S₂

Molecular weight

1,815.1 g/mol

CAS number

221231-10-3

Targets

Glutathione S-transferase LANCL1 (LanC-like protein 1) (gene LANCL1): binder (proposed)Evidence: primary literatureLanC-like protein 2 (gene LANCL2): activator (proposed)Evidence: proposed

Development

Lateral Pharma Pty Ltd (current LAT8881 trials). Highest phase: phase 2.

Identifiers

PubChem 71300630, ChEMBL CHEMBL6068615, UNII 7UP768IP4M

Full sequence, SMILES and InChIKey

Three-letter sequence
H-Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-OH (disulfide Cys7-Cys14)

InChIKey
GVIYUKXRXPXMQM-BPXGDYAESA-N

SMILES
CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CCCNC(=N)N)CO)C(C)C)CCC(=O)O)CO)C(=O)NCC(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CC=C(C=C3)O)N

See charge, composition and 3D structure on the Scientific page

The evidence

What AOD-9604 studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Animal and lab studies onlyNo study in people has results. ClinicalTrials.gov lists 3 trials.

Weight and appetite

13 results · 13 animal

In obese mice, AOD9604 was linked to more fat burning in the body. International journal of obesity and related metabolic disorders, 2001

Top results

In obese mice, AOD9604 was linked to more fat burning in the body. (International journal of obesity and related metabolic disorders, 2001)
In obese mice, AOD9604 reduced weight gain. (International journal of obesity and related metabolic disorders, 2001)
In obese mice, AOD9604 given for two weeks lowered body fat. (Endocrinology, 2001)

Pain

9 results · 6 animal · 3 lab

In rodents with nerve injury pain, LAT8881 reversed pain from light touch. Pain, 2026

Top results

In rodents with nerve injury pain, LAT8881 reversed pain from light touch. (Pain, 2026)
In rodents with nerve injury, LAT8881 reduced abnormal spontaneous nerve firing at the dorsal root ganglion. (Pain, 2026)
In rodents with nerve injury, LAT8881 reduced wind-up, a build-up of pain signals in the spinal cord. (Pain, 2026)

Bones and joints

6 results · 6 animal

In rabbits with knee arthritis, joint damage scores were lower with AOD9604 than with saline. Annals of clinical and laboratory science, 2015

Top results

In rabbits with knee arthritis, joint damage scores were lower with AOD9604 than with saline. (Annals of clinical and laboratory science, 2015)
In rabbits with knee arthritis, cartilage tissue damage scores were lower with AOD9604 than with saline. (Annals of clinical and laboratory science, 2015)
In rabbits with knee arthritis, joint damage scores were lower with AOD9604 plus HA than with HA alone. (Annals of clinical and laboratory science, 2015)

Blood sugar

3 results · 3 animal

In obese mice, AOD9604 did not raise blood sugar, unlike human growth hormone. International journal of obesity and related metabolic disorders, 2001

Top results

In obese mice, AOD9604 did not raise blood sugar, unlike human growth hormone. (International journal of obesity and related metabolic disorders, 2001)
In obese rats, AOD9604 did not harm insulin sensitivity, unlike human growth hormone. (Hormone research, 2000)
In obese mice, AOD9604 did not lower insulin release, unlike human growth hormone. (International journal of obesity and related metabolic disorders, 2001)

Infections

3 results · 3 animal

In mice with severe flu, daily LAT8881 into the nose from day 1 after infection improved resistance to disease. Clinical & translational immunology, 2023

Top results

In mice with severe flu, daily LAT8881 into the nose from day 1 after infection improved resistance to disease. (Clinical & translational immunology, 2023)
In mice with severe flu, daily LAT8881 into the nose was linked to lower amounts of infectious virus. (Clinical & translational immunology, 2023)
In mice with severe flu, LAT8881 plus oseltamivir lowered disease severity markers more than either one alone. (Clinical & translational immunology, 2023)

Immune system and inflammation

2 results · 2 animal

In mice with severe flu, daily LAT8881 into the nose was linked to more protective lung immune cells. Clinical & translational immunology, 2023

Top results

In mice with severe flu, daily LAT8881 into the nose was linked to more protective lung immune cells. (Clinical & translational immunology, 2023)
In mice with severe flu, daily LAT8881 into the nose was linked to lower levels of inflammatory signals. (Clinical & translational immunology, 2023)

All 10 AOD-9604 studies by area Open the Scientific page

Key AOD-9604 studies

Studies in people come first, then studies in animals and in the lab.

Animals
Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment
Heffernan et al. 2001 · International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity · cited by 25
7 results
Animals
The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice
Heffernan et al. 2001 · Endocrinology · cited by 19
9 results
Animals
Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone
Ng et al. 2000 · Hormone research · cited by 17
3 results
Animals
Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model
Kwon et al. 2015 · Annals of clinical and laboratory science · cited by 9
6 results
Animals
Naturally derived cytokine peptides limit virus replication and severe disease during influenza A virus infection
Harpur et al. 2023 · Clinical & translational immunology · cited by 8
7 results

All 10 AOD-9604 studies

AOD-9604 clinical trials

ClinicalTrials.gov lists 3 trials of AOD-9604. 0 are active or planned, and 3 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

Oral LAT8881 in Neuropathic Pain

Phase 2completed53 people

A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine

Phase 2completed21 people

A Two-part Proof-of-Concept Study Assessing the Safety and Efficacy of LAT8881 in Lumbar Radicular Pain

Phase 1completed26 people

Status and safety

Is AOD-9604 approved?

FDA

United States

Not approved

No approved medicine contains it.

EMA

European Union

Not approved

No approved medicine contains it.

WADA

Sport

Banned

On the 2026 Prohibited List, section S2.

No. Not approved for any use. Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 8 Oct 2026). Banned in sport (WADA S2).

Laws and labels change, so check the regulator for the current status.

AOD-9604 side effects and safety

PepBank has 3 safety results from studies of AOD-9604. None of them come from studies in people, so they do not show what happens in people.

Safety results from studies (3)

In obese mice, AOD9604 did not raise blood sugar, unlike human growth hormone. (International journal of obesity and related metabolic disorders, 2001)
In obese rats, AOD9604 did not harm insulin sensitivity, unlike human growth hormone. (Hormone research, 2000)
In obese mice, AOD9604 did not lower insulin release, unlike human growth hormone. (International journal of obesity and related metabolic disorders, 2001)

See every safety result on the Scientific page

Doses studied (3 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
500 microg/kg body weight daily	Animal	rats	oral	19 days	Study in live animals	Ng 2000
0.25 mg AOD9604 weekly	Animal	rabbit	intra-articular	4-7 weeks	Study in live animals	Kwon 2015
0.25 mg AOD9604 with 6 mg HA weekly	Animal	rabbit	intra-articular	4-7 weeks	Study in live animals	Kwon 2015

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

People inject AOD-9604 for fat loss, most often 300 mcg once a day on an empty stomach. Reports give a range of 250 to 500 mcg a day for several weeks to a few months. The main human weight-loss trial did not beat placebo.

Reported routines and cautions

What people use it for

Fat lossS1S2
Joint use: injected into a joint, sometimes with hyaluronic acid (S2 says this is not a standard self-administration route)S2

Reported regimens

Regimens that community sources report for AOD-9604. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Fat loss attempt	subcutaneous injectionpowder mixed with bacteriostatic water; injected fasted	300 mcg per dose	once daily, fasted (morning)	12 to 16 weeks, or several weeks to a few months	2 sources agree on 300 mcg once daily, fasted; duration differs: 12 to 16 weeks vs several weeks to a few months; both sources carry seller links	S1S2
Lower or split dose	subcutaneous injection	250 mcg per dose	once daily (S2) or twice daily (S1)	4 to 8 weeks (S2) or 12 to 16 weeks (S1)	sources differ: 250 mcg twice daily for 12 to 16 weeks (S1) vs 250 mcg once daily for 4 to 8 weeks (S2); both sources carry seller links	S1S2
Higher daily dose	subcutaneous injection	500 mcg per dose	once daily	8 to 12 weeks	2 sources give 500 mcg once daily as the top of the reported range (S1: 8 to 12 weeks, used by some clinics; S2: several weeks); both sources carry seller links	S1S2
Oral or sublingual forms (niche)	oralcapsule, tablet or oral spray	300 to 600 mcg per dose	once daily	12 weeks or more	sources differ: S1 gives 300 to 600 mcg once daily; S2 says oral doses vary widely and are not standardized; both sources carry seller links	S1S2

Reported side effects

few side effects reportedS1

Reported benefits (claims, not shown in trials)

modest, gradual fat loss, often noticed at 8 to 12 weeksS1
no change in appetite or blood sugarS1
a significant portion of users report little noticeable effectS1

Cautions

The largest trial did not show a significant weight loss effect. The wiki says this is often played down.S1S2
GRAS status as a food ingredient is not approval for use as a drug.S1
Products from research-chemical suppliers lack pharmaceutical standardization. Purity, potency and contaminant levels may vary.S3
The wiki says WADA prohibits AOD-9604 at all times, in and out of competition.S3

Status notes

A law-firm page dated 2025-11-19 says FDA had proposed not to include AOD-9604 on the bulk drug substances list, and that compounding is prohibited. This is a proposal, and the page may be out of date.S4
On 2026-02-27 the HHS secretary announced a plan to move about 14 of 19 restricted peptides, including AOD-9604, back to compounding category 1. This is a plan, not an FDA approval. AJMC (2026-08-21) says it was expected to take effect by 2026-04-23. Whether it did is not confirmed here. AJMC does not name AOD-9604 among the peptides the July 2026 FDA advisory panel reviewed.S5

Community sources

S1AOD-9604: Community Protocols & Reportspeptideprotocolwiki.comcarries seller links, not linked
S2AOD-9604: dosage, benefits and risksoutliyr.comcarries seller links, not linked
S3AOD-9604: Riskspeptideprotocolwiki.comcarries seller links, not linked
S4Deep dive: regulatory status of popular compounded peptides (2025-11-19) (opens in a new tab)djholtlaw.com
S55 things to know about the FDA's peptide reversal (2026-08-21) (opens in a new tab)ajmc.com

Gaps

No public forum posts with checkable doses were found, and Reddit cannot be fetched here. Both dosing sources are secondary summaries and both carry seller links or rankings. The WADA statement page could not be fetched, so the WADA line rests on the wiki. The law-firm page (S4) blocks automated fetches; its text was read from a public archive copy dated 2026-07-01. Current FDA compounding status after the 2026 changes is not confirmed.

Questions and more

Ask a question about AOD-9604

The answer links to every study it uses.

What does the evidence say about AOD-9604?Is AOD-9604 tested in people?Compare with Dulaglutide (Trulicity)Compare with Liraglutide

Sources

Database: PepBank data for AOD-9604 (data version 308560)
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about AOD-9604

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).

AOD-9604

Not approvedBanned in sport

Also known as AOD9604, LAT-8881, LAT8881, Tyr-hGH(177-191), Tyr-somatostatin (177-191), hGH fragment 176-191

What it is

Synthetic fragment, 16 amino acids

Approval

Not approved for any use

In sport

Banned in sport (WADA S2)

Studies

10 studies with results. 7 of them gave AOD-9604, with 44 results.
36 in animals8 in lab cells

Clinical trials

3 registered: 0 active or planned, 3 with posted results

Community use

Fat loss; Joint use: injected into a joint, sometimes with hyaluronic acid (S2 says this is not a standard self-administration route)

Dose as reported

Class

Species

Route

Duration

Design

Source

500 microg/kg body weight daily

Animal

rats

oral

19 days

Study in live animals

Ng 2000

0.25 mg AOD9604 weekly

Animal

rabbit

intra-articular

4-7 weeks

Study in live animals

Kwon 2015

0.25 mg AOD9604 with 6 mg HA weekly

Animal

rabbit

intra-articular

4-7 weeks

Study in live animals

Kwon 2015

Context

Route

Amount

How often

How long

Agreement

Sources

Fat loss attempt

subcutaneous injectionpowder mixed with bacteriostatic water; injected fasted

300 mcg per dose

once daily, fasted (morning)

12 to 16 weeks, or several weeks to a few months

2 sources agree on 300 mcg once daily, fasted; duration differs: 12 to 16 weeks vs several weeks to a few months; both sources carry seller links

S1S2

Lower or split dose

subcutaneous injection

250 mcg per dose

once daily (S2) or twice daily (S1)

4 to 8 weeks (S2) or 12 to 16 weeks (S1)

sources differ: 250 mcg twice daily for 12 to 16 weeks (S1) vs 250 mcg once daily for 4 to 8 weeks (S2); both sources carry seller links

S1S2

Higher daily dose

subcutaneous injection

500 mcg per dose

once daily

8 to 12 weeks

2 sources give 500 mcg once daily as the top of the reported range (S1: 8 to 12 weeks, used by some clinics; S2: several weeks); both sources carry seller links

S1S2

Oral or sublingual forms (niche)

oralcapsule, tablet or oral spray

300 to 600 mcg per dose

once daily

12 weeks or more

sources differ: S1 gives 300 to 600 mcg once daily; S2 says oral doses vary widely and are not standardized; both sources carry seller links

S1S2

AOD-9604

AOD-9604 at a glance

What is AOD-9604?

The history of AOD-9604

AOD-9604 structure and chemistry

What AOD-9604 studies show

Weight and appetite

Pain

Bones and joints

Blood sugar

Infections

Immune system and inflammation

Key AOD-9604 studies

AOD-9604 clinical trials

Is AOD-9604 approved?

AOD-9604 side effects and safety

How people use it

What people use it for

Reported regimens

Reported side effects

Reported benefits (claims, not shown in trials)

Cautions

Status notes

Community sources

Ask a question about AOD-9604

Related peptides

Sources

AOD-9604

AOD-9604 at a glance

What is AOD-9604?

The history of AOD-9604

AOD-9604 structure and chemistry

What AOD-9604 studies show

Weight and appetite

Pain

Bones and joints

Blood sugar

Infections

Immune system and inflammation

Key AOD-9604 studies

AOD-9604 clinical trials

Is AOD-9604 approved?

AOD-9604 side effects and safety

How people use it

What people use it for

Reported regimens

Reported side effects

Reported benefits (claims, not shown in trials)

Cautions

Status notes

Community sources

Ask a question about AOD-9604

Related peptides

Sources